Table 2.

Effects of CXB, MK886, LY171883, FB1, CXB + MK886, CXB + LY171883, or CXB + MK886 + FB1 on HT29 and Caco-2 cell apoptosis as determined by Annexin V test using flow cytometry

DrugsApoptotic cells (% of total)
HT29 cellsCaco-2 cells
None2.3 ± 1.23.0 ± 0.3
CXB (10 μmol/L)7.7 ± 1.36.7 ± 0.5
MK886 (10 μmol/L)4.0 ± 2.46.2 ± 0.3
LY171883 (10 μmol/L)4.6 ± 1.86.6 ± 0.6
FB1 (10 μmol/L)3.1 ± 0.32.2 ± 1.1
CXB + MK88634.7 ± 1.5*,34.1 ± 0.1*,
CXB + LY17188333.6 ± 0.4*,35.1 ± 1.0*,
CXB + MK886 + FB18.6 ± 1.93.5 ± 2.3
  • * Significant increase compared with basal condition (P < 0.05).

  • Significant increase compared with treatment with CXB, MK886, or LY171883 alone (P < 0.05).

  • Significant decrease compared with treatment with CXB + MK886 (P < 0.05).